Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
CAR T-cell therapy is a promising treatment for patients with multiple myeloma, whose disease has relapsed or is not responding to (refractory) prior treatments. It is a highly-specialized therapy that involves genetically modifying a patient's own T
cells to attack their multiple myeloma using a target called B-cell maturation antigen (BCMA). The FDA has approved Abecma (idecabtagene vicleucel), the first CAR T-cell therapy for multiple myeloma. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC)
is a leader in bringing new CAR T-cell therapies to patients in need and led the clinical trial that led to FDA approval of Abecma.
Abecma is approved for multiple myeloma that has relapsed after or is refractory to at least four prior treatments. The clinical trial of Abecma showed the CAR T-cell therapy to be highly effective for patients whose disease had relapsed after or not responded to multiple prior treatments.
Patients are evaluated carefully to determine if this therapy is appropriate for them. Learn more about CAR T-cell therapy.
DF/BWCC also offers clinical trials of other CAR T-cell therapies for multiple myeloma.
Grandmother Living Active Life after CAR-T TreatmentThe FDA recently approved the first CAR T-cell therapy for multiple myeloma. Nikhil Munshi, MD, and clinical trial participant, Susan Voigt share what this significant advance means for patients.
Contact Information for CAR T-Cell Therapy
For more information about CAR T-cell therapy, please call 877-801-CART (2278).